So Much Blood

Original Article ↗ Hacker News Discussion ↗

US trade data shows that human blood and blood-derived products account for around 0.7% of U.S. goods exports, a lot less than some widely repeated claims but still a surprisingly large and strategically important share. Commenters explore why the U.S. dominates this trade — especially its permissive, often exploitative paid-plasma system and looser rules compared with countries that ban compensation — and how this creates dependence abroad, particularly in Europe. The thread also delves into the ethics and safety of monetizing blood and plasma, past scandals involving tainted supplies, and how opaque classification systems and data tooling can mislead journalists and policymakers about the true scale of the “blood economy.”

What the article showed about “blood exports” and data

  • Commenters highlight the core point: blood-related products are ~0.7% of US exports, not ~2% nor a “top 10 export,” and this is still surprisingly high.
  • Several people praise the careful use of primary trade data (HS codes, USITC site) and note how easy it is for journalists/tools to repeat an eye‑catching but wrong figure.
  • One commenter traces the original error to HS code 3002 (“blood; antisera; vaccines; cultures…”), often truncated to just “Human blood,” which misleads dashboards and casual analysts.
  • Some wonder whether “deep research” LLM tools could replicate this kind of analysis; others doubt it, saying current systems favor consensus secondary sources over careful primary-data work.

HN title norms and discoverability

  • Multiple comments criticize HN’s insistence on original article titles, arguing:
    • Many original titles are opaque or clickbait-ish; better summaries would help scanning.
    • There’s inconsistency: if an original title is too long, submitters effectively do get to choose a new one.
  • Writers say this makes them hesitant to share posts whose titles only make sense “in hindsight.”

Blood and plasma donation systems

  • Large subthread on legal and ethical differences:
    • In parts of Europe (e.g., Netherlands, Italy, France, etc.), donor payment is banned; appeals emphasize altruism and concerns that payment incentivizes lying about health.
    • In the US and a few other countries (Austria, Czech Republic, Germany), plasma donors are paid; whole blood is typically unpaid, though “compensation” like gift cards is common.
    • Clarification: In the US you can sell plasma (via apheresis) but not red cells or platelets.
  • Some argue paying donors degrades safety via socioeconomic selection; others say contamination risks are managed with testing and that bans just create shortages and reliance on US exports.
  • Several draw a parallel to organ markets (e.g., kidneys), noting Iran’s paid system and debates over exploitation vs. reducing waitlists.

Economics, exploitation, and scandals

  • US dominance in plasma exports is attributed to:
    • Legal payment, aggressive private centers targeting poorer populations, and countries discouraged by WHO from commercialized systems.
  • Commenters mention:
    • Historical scandals: tainted US prison blood exported to other countries (notably UK) causing HIV/Hep C infections, now costing billions in compensation.
    • Anecdotes of prepaid plasma “donation” cards being spent on alcohol, reinforcing perceptions that donors are financially desperate.
  • Some see the export dependence as a fragile supply-chain issue; others argue blood infrastructure can be ramped locally and is not a serious “trade war” lever.

Pricing, “nonprofits,” and CEO pay

  • Strong criticism of blood banks and plasma companies:
    • Donors are unpaid or poorly paid while hospitals are billed hundreds to thousands per unit.
    • “Nonprofit” blood centers cited with CEO pay from hundreds of thousands up to several million dollars, plus PE-style financialization.
  • Debate:
    • One side calls such compensation clearly excessive, especially for quasi-public services.
    • The other side argues CEO labor markets and opportunity cost justify mid‑six‑figure salaries, even in nonprofits; skeptics respond with “tournament theory” and board capture arguments.

Miscellaneous side threads

  • Discussion of US vs European rules on donation frequency and safety testing.
  • Observations that plasma can be used for drugs, cosmetics, and high-value specialty products; some rare donors are allegedly compensated very highly.
  • Jokes, puns, and minor side topics (convenience-store beer, tariffs, vampire jokes, etc.) appear but don’t affect the main themes.